Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
ZVRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.20 - $9.76
Previous CloseN/A
Volume189.47K
Average Volume (3M)368.09K
Market Cap
$427.54M
Enterprise Value$337.68M
Total Cash (Recent Filing)$18.41M
Total Debt (Recent Filing)$82.05M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 11, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding53,375,930
10 Day Avg. Volume323,715
30 Day Avg. Volume368,094
Standard Deviation1.32
R-Squared0.02
Alpha0.16
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.25
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.77
Enterprise Value/Ebitda-4.58
Forecast
1Y Price Target
$21.80Price Target Upside197.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Zevra Therapeutics News
PremiumCompany Announcements
Zevra Therapeutics Sells Priority Review Voucher for $150M
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe sale of the Rare Pediatric Disease Priority Review Voucher for $150M provides a significant infusion of non-dilutive capital to strengthen the company's balance sheet.
Product LaunchFDA approval of Miplyffa marks it as the first approved therapy for Niemann-Pick disease type C in the US, potentially allowing for rapid adoption among patients.
Bears Say
Sales ChallengesThere is more caution on assumed OLPRUVA sales ramp given early challenges, leading to a reduction in near-term and peak sales until Zevra demonstrates traction.
---
Ownership Overview
0.64% Insiders
10.76% Mutual Funds
35.42% Other Institutional Investors
42.57% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZVRA FAQ
What was Zevra Therapeutics’s price range in the past 12 months?
Zevra Therapeutics lowest stock price was $4.20 and its highest was $9.76 in the past 12 months.
What is Zevra Therapeutics’s market cap?
Zevra Therapeutics’s market cap is $427.54M.
When is Zevra Therapeutics’s upcoming earnings report date?
Zevra Therapeutics’s upcoming earnings report date is Mar 11, 2025 which is in 7 days.
How were Zevra Therapeutics’s earnings last quarter?
Zevra Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.411 by -$0.279.
Is Zevra Therapeutics overvalued?
According to Wall Street analysts Zevra Therapeutics’s price is currently Undervalued.
Does Zevra Therapeutics pay dividends?
Zevra Therapeutics does not currently pay dividends.
What is Zevra Therapeutics’s EPS estimate?
Zevra Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Zevra Therapeutics have?
Zevra Therapeutics has 53,375,930 shares outstanding.
What happened to Zevra Therapeutics’s price movement after its last earnings report?
Zevra Therapeutics reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.411. Following the earnings report the stock price went up 1.05%.
Which hedge fund is a major shareholder of Zevra Therapeutics?
Currently, no hedge funds are holding shares in ZVRA
---
Zevra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.80 (197.41% Upside)
$21.80 (197.41% Upside)
Blogger Sentiment
Bullish
ZVRA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 117.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.76%
12-Months-Change
Fundamentals
Return on Equity
-123.76%
Trailing 12-Months
Asset Growth
37.82%
Trailing 12-Months
Company Description
Zevra Therapeutics
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
---
ZVRA Company Deck
---
ZVRA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements with the approval and launch of MIPLYFFA, receiving a priority review voucher, and positive clinical pipeline developments. However, these were balanced by challenges with OLPRUVA's underperformance, increased expenses, and discontinued development activities.Read More>---
ZVRA Stock 12 Month Forecast
Average Price Target
$21.80
▲(197.41% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Vertex Pharmaceuticals
―
Prothena
―
SAGE Therapeutics
―
Best Analysts Covering ZVRA
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+22.72%
reiterated a buy rating 6 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +22.72% per trade.
---